Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DPBM on CNBC tonight!!!
UPDA SIMPLE...........
Does anyone know the share structure of GZFX TIA
STTK another run today for sure look at her gap!!
Agreed, i think tommorow we break our .80 resistance and probably hear into the .90's maybe pushing 1.00 if the volume follows us!
GBIW had good news this afternoon looking real good for tommorow
Genesis Bioventures Announces Results From Testing of Mad Cow Disease and Scrapie Rapid Assays
NEW YORK, NY, March 16 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) is pleased to announce that the Rapid Prion Detection Assays developed by Prion Developmental Laboratories (PDL), a portfolio company of GBI, have been successfully tested at the Veterinary Laboratories Agency in Weybridge, England.
The BSE Assay, designed to detect the prion disease, Bovine Spongiform Encephalopathy (BSE) or Mad Cow disease, achieved the diagnostic test performance which allows PDL to apply for regulatory approval. The results that were achieved establish the Rapid Assay in the same performance class as the leading commercially approved tests presently being used in the cattle industry worldwide, but with a faster turn around time.
'We are satisfied with the performance of our assay,' said Dr. Rubenstein, Chief Scientific Officer of PDL. 'Dr. Petersen and I have worked over the last six months to increase the sensitivity and specificity of the assay that led to these results. We are equally pleased to announce that the Scrapie assay for sheep also achieved comparable results. '
'The results we achieved on the positive and negative samples for both BSE and Scrapie meet the regulatory requirements the assays must demonstrate to achieve approval to sell the tests in all major markets in the world, including the US, Canada, Japan, and the European Community,' said Dr. Petersen, CEO of PDL. 'Over the coming months we will be working closely with GBI and regulatory agencies in the major markets to prepare and submit approval applications for both tests.'
'These results complement the Chronic Wasting Disease rapid assay that PDL completed last year that received USDA approval,' said Greg McCartney President and CEO of GBI. We are very pleased that this phase of the test development is completed and we can now seek regulatory approvals for commercialization.'
About Prion Development Laboratories
PDL is a leading biotechnology company that researches, develops and produces advanced diagnostic and food safety monitoring tests for human and animal diseases caused by prions. Genesis Bioventures, Inc. has a significant investment in PDL.
About Genesis Bioventures, Inc.
Genesis Bioventures, Inc. is a biomedical development corporation focusing on the development and marketing of novel diagnostics and therapeutics in oncology and neurodegenerative diseases.
Statements in this press release that are not strictly historical facts are 'forward looking' statements (identified by the words 'believe', 'estimate', 'project', 'expect' or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT:
GBI Investor Relations: (604) 542-0820, gbi@gnsbio.com,
www.gnsbio.com
Experigen: (310) 443-4100, info@experigen.com,
www.experigen.com
DOC.....to be on CNBC tommorow morning
SPRX starting to look good this morning ask is starting to back off and word is getting out about their patent news!!!
SpectRx, Inc. Granted Patent for Non-invasive Cervical Cancer Detection Technology; Guided Therapeutics Device in FDA Pivotal Clinical Trial
NORCROSS, Ga., Mar 09, 2006 (BUSINESS WIRE) -- SpectRx, Inc. (SPRX, Trade) today announced it was granted a patent for the unique method in which its non-invasive cervical cancer detection technology helps to define the location of disease and reduce errors in data collection. U.S. Patent 7,006,220 recognizes that the technology is capable of increasing the spatial resolution of changes in tissue in order to more efficiently detect diseases such as cancer.
"This patent is an important addition to our portfolio of non-invasive detection and monitoring intellectual property," said Mark Faupel, president and chief operating officer of Guided Therapeutics, Inc., the SpectRx subsidiary company formed to commercialize the non-invasive cervical cancer detection device. "The patent provides for a more efficient method of determining tissue characteristics and may be useful for detecting cervical disease and possibly other cancers as well."
The patent claims a device that spectroscopically measures tissue at a high resolution while avoiding cross talk, or ambiguity, between measured locations. This is done by moving a component of the device and repeating interrogations on a different set of locations of tissue using both fluorescence and reflectance spectroscopy. The method claimed allows for a short measurement time thereby reducing potential errors while allowing the use of cost effective instrumentation.
The non-invasive cervical cancer detection device, which is undergoing FDA pivotal clinical trials, uses proprietary technology to identify cancers and precancers painlessly and non-invasively by analyzing light reflected from the cervix. The device creates an image of the cervix that highlights the location and severity of disease. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the non-invasive test does not require a tissue sample or laboratory analysis, and results are available immediately. To date, more than 1,800 women have been tested with prototypes of the non-invasive cervical cancer detection device. Research and commercialization of a product are being funded, in part, by grants from the National Cancer Institute (NCI).
According to published reports, cervical cancer is the third most common cancer among women worldwide. Globally, there are approximately 471,000 cases of cervical cancer diagnosed annually and approximately 233,000 deaths per year. Approximately 60 million Pap tests are performed annually in the United States.
About Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a subsidiary of SpectRx, Inc. Guided Therapeutics is developing and plans to bring to market the non-invasive cancer detection technology. SpectRx intends to separately finance Guided Therapeutics. For more information, visit www.guidedtherapeutics.com.
About SpectRx, Inc.
SpectRx, Inc. (SPRX, Trade) is a diabetes management company developing and providing innovative solutions for insulin delivery and glucose monitoring. SpectRx markets the SimpleChoice(R) line of innovative diabetes management products, which include insulin pump disposable supplies. SpectRx also plans to develop a consumer device for continuous glucose monitoring. For more information, visit www.spectrx.com.
The Guided Therapeutics device is an investigational device and is limited by federal law to investigational use.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from SpectRx's actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time in SpectRx's reports under the heading "Risk Factors" filed with the SEC, including SpectRx's Annual Report on Form 10-K for the fiscal year ended December 31, 2004 and subsequent quarterly reports.
SOURCE: SpectRx, Inc.
SpectRx, Inc., Norcross
Bill Wells, 770-242-8723
Copyright Business Wire 2006
SPRX has very very good news today about a patent that they had received aproval for, for cervical cancer, Volume was still kind of light on it today and think that this could be a delayed news runner. There has been plenty of very small companys where the news dossent exactly get out till a few days later and i think this is once of them. Watch it tommorow.
SpectRx, Inc. Granted Patent for Non-invasive Cervical Cancer Detection Technology; Guided Therapeutics Device in FDA Pivotal Clinical Trial
NORCROSS, Ga., Mar 09, 2006 (BUSINESS WIRE) -- SpectRx, Inc. (SPRX, Trade) today announced it was granted a patent for the unique method in which its non-invasive cervical cancer detection technology helps to define the location of disease and reduce errors in data collection. U.S. Patent 7,006,220 recognizes that the technology is capable of increasing the spatial resolution of changes in tissue in order to more efficiently detect diseases such as cancer.
"This patent is an important addition to our portfolio of non-invasive detection and monitoring intellectual property," said Mark Faupel, president and chief operating officer of Guided Therapeutics, Inc., the SpectRx subsidiary company formed to commercialize the non-invasive cervical cancer detection device. "The patent provides for a more efficient method of determining tissue characteristics and may be useful for detecting cervical disease and possibly other cancers as well."
The patent claims a device that spectroscopically measures tissue at a high resolution while avoiding cross talk, or ambiguity, between measured locations. This is done by moving a component of the device and repeating interrogations on a different set of locations of tissue using both fluorescence and reflectance spectroscopy. The method claimed allows for a short measurement time thereby reducing potential errors while allowing the use of cost effective instrumentation.
The non-invasive cervical cancer detection device, which is undergoing FDA pivotal clinical trials, uses proprietary technology to identify cancers and precancers painlessly and non-invasively by analyzing light reflected from the cervix. The device creates an image of the cervix that highlights the location and severity of disease. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the non-invasive test does not require a tissue sample or laboratory analysis, and results are available immediately. To date, more than 1,800 women have been tested with prototypes of the non-invasive cervical cancer detection device. Research and commercialization of a product are being funded, in part, by grants from the National Cancer Institute (NCI).
According to published reports, cervical cancer is the third most common cancer among women worldwide. Globally, there are approximately 471,000 cases of cervical cancer diagnosed annually and approximately 233,000 deaths per year. Approximately 60 million Pap tests are performed annually in the United States.
About Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a subsidiary of SpectRx, Inc. Guided Therapeutics is developing and plans to bring to market the non-invasive cancer detection technology. SpectRx intends to separately finance Guided Therapeutics. For more information, visit www.guidedtherapeutics.com.
About SpectRx, Inc.
SpectRx, Inc. (SPRX, Trade) is a diabetes management company developing and providing innovative solutions for insulin delivery and glucose monitoring. SpectRx markets the SimpleChoice(R) line of innovative diabetes management products, which include insulin pump disposable supplies. SpectRx also plans to develop a consumer device for continuous glucose monitoring. For more information, visit www.spectrx.com.
The Guided Therapeutics device is an investigational device and is limited by federal law to investigational use.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from SpectRx's actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time in SpectRx's reports under the heading "Risk Factors" filed with the SEC, including SpectRx's Annual Report on Form 10-K for the fiscal year ended December 31, 2004 and subsequent quarterly reports.
SOURCE: SpectRx, Inc.
SpectRx, Inc., Norcross
Bill Wells, 770-242-8723
Copyright Business Wire 2006
When you open up that weblink go down to the FEb 28th Admendment and you will see the 6,000,000,000
WOW!!!! i knew they where diluting but i figured just the rest of the 1bill but to see 6 billion holy cow
MSS Awsome chart set up, Huge buys comming in EOD 20k blocks, and closed very very strong!! at HOD.. Keep an eye on it again tommorow!!
Thoughts on it anyone?
Once JEFF backs off the ask this stock seems to move up very very easly im also hearing that the company got approval of their patent that they had applied for so that may be the reason for them dumping some shares to raise money so they can go through with the patent deal just my thoughts but we will see what happens
This stock is going to Rock today!!! look at some of the other subbers that started to run IVOC now oveer .0025 USXP now over .04 fromm .0004 This is CNES's Turn!!!!
CHMD Thouhgts on it for tommorow.....
I was looking at the past charts on this stock and when it has a good run it tends to follow that patter for a few days i noticed today was a very well day for it and havent had the time to do to much DD on why it ran but any insight would bbe apreciated thanks.
Stockster latest news letter
STOP! - "We found the Motherload!" - Ticker Symbol = INFO
Get in NOW with Potential Short-Term Profits of 1000%+
INFO has been the Largest % Gainer on Nasdaq 2 days in a row!
And Weds., Thurs., and Friday will be the same way! The
TSUNAMI that is INFO hasn't even started!
There is Only 1 HOT Stock to Buy Right Now!= INFO
HOT NASDAQ = MetroOne
Ticker Symbol = INFO
Feb 17th Pick Price = $0.33
Current Price = $0.93 +181%
Target Price = $3.50
52 Week High = $1.49
Market Cap. = 26 Million
Industry: Mobile Phone Directory Assistance &
the Exploding Mobile Content Business!!!!!!!!!!!!!
HighLights: This stock was trading at $43.00!!!
Lawsuits have been settled and moving forward!
As per their last 10Q, they have $35 Million CASH!
That is 4 times their Market Cap. CASH PER
SHARE IS $1.32 Our Short-term target is $3.50
Disclosure: We Own Shares
Recommendation: THIS IS THE MEGA BUY OF 2006!!!!!
To join our mailing list please send an email to TheStockster2006@Yahoo.com
I said if there is a talk about a R/S then i am getting out of this stock i see nothing wrong with that at all. and the reason why there is no doubt about dilution is simple look at the friggen amount of volume the past 4 days it has topped the supposed O/S. There is dilution going on right now wether you want to beleave it or not.
Looking back at the charts and volume with this much down side .0002 could be our bottom and a great entry to eighther load up or average down like me. But with out a doubt Dilution is going on, whitch is ok if the company needs to raise funds but if people start talking bout a R/S im out.
I currantly own PHBT at higher levels and am planning on averging down. But you have to beleave there is dilution going on without a doubt. Just look at the volume over the past few days its near record highs and its almost all sells. I for one think i will still hold but i am definitly going to sleep on it. We all have seen what dilution can and ultimately will do to the company if they dont have limits but for now i will hold.
For every sell there is a buy for every buy there is a sell. Its just a matter of momentum and what happened first. If someone hits the bid then in sence it is a sell, if someone hits the ask then it is a buy. Im not going to argue this i was just stating a fact that there was a big sell/buy what ever you wanna call it on the bid at .0004
Well when there is someone sitting at the bid at .0004 and the ask is .0005 and an order comes in for .0004 then it is a sell, if the bid was .0003 and the ask was .0004 and it came in at .0004 then it would be a buy. Pretty Simple.
Wow 5mm sell at .0004 on bid at 14:01 who has this many shares to just be dumping
Fringe.....
I understand that chart i see what you are saying, but thats my point. you see on that chart that that it has 2 solid .0003 days then bounces .0007 then retrances to .0003 for a solid 2 days then bounces .001 well now its in another Re-trace and it has not had its solid 2 days of selling in .0003 I own and watch this stock alot like everyone in here and in watching this stock its obviouse to see it accumilates alot between .0004-.0005 then has its one or 2 days od heavy selling in .0003 range then bounces. Thats why i beleave it has to come back and go through the .0003's but like you said you never know with a sub penny. Exspecially a sub penny with not much volume.
UBSS moved back down to .0005 on the ask.... Well that mis-print looks nice while it last. Im really exspecting this stock to move back into the .0003's befour it breaks out just look at the chart from the last 2 runs. It has to have atleast 2 solid days of .0003 sells befour it moves. Now if this happens or not i dont know but thats according to the charts so good luck everyone.!
KAMLOOPS, British Columbia--(BUSINESS WIRE)--July 21, 2005--
Greyfield Capital Inc. (Pink Sheets:GRYF) will be
releasing its unaudited financials Friday, July 22. This will be
followed up in mid- to late August with the release of the audited
financials.
New management of Greyfield is committed to having an open
relationship with all of its shareholders.
About Greyfield Capital
Canadian Autorama is the Canadian subsidiary of Greyfield Capital
and is a highly profitable, fast-growing premium automobile dealership
in Canada. Canadian Autorama has been in operation for the last three
years, and has experienced explosive growth and is quickly becoming
the largest automobile dealership in central Canada.
CAUTIONARY STATEMENT: This news release may include
forward-looking statements within the meaning of Section 21E of the
United States Securities Exchange Act as amended, and/or the U.S.
Private Securities Litigation Reform Act of 1995. All statements
involve various risks and uncertainties. There can be no assurance
that such statements will prove to be accurate, and actual results and
future events could differ materially from those anticipated in such
statements that involve various risks and uncertainties. All
forward-looking statements in this release are expressly qualified by
this notice.
With the close above .003 i think this sets us up for a nice run tommorow and possibly monday but one day at a time . The thing i like about this is that the news that we are waiting for actually has a date of when it is going to come out unlike the past where it has all been rummers and when the numbers come out and everyone who was on the side lineswaiting for the numbers jump in this stock should really take off fast good luck to everyone tommorow and hope this thing fly's